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A B S T R A C T   
Mutations in ABCA4 gene are causative for autosomal recessive Stargardt disease (STGD1), the most common inherited retinal dystrophy. Here, we report the 
generation of an induced pluripotent stem cell (iPSC) line from a STGD1 patient carrying biallelic c.[5461–10T>C;5603A>T];[6077T>C] mutations in the ABCA4 
gene. Episomes carrying OCT4, SOX2, KLF4, L-MYC, LIN28 and mp53DD were employed for the reprogramming of patient-derived fibroblasts. This iPSC line 
expressed comparable pluripotency markers as in a commercially available human iPSC line, displayed normal karyotype and potential for trilineage differentiation, 
and were negative for both reprogramming episomes and mycoplasma test.   
Resource Table:  
Unique stem cell line identifier LEIi018-A 
Alternative name(s) of stem cell 
line 
1607ips6 
Institution Lions Eye Institute 
Contact information of 
distributor 
Samuel McLenachan: smclenachan@lei.org.au 
Fred K. Chen: fredchen@lei.org.au 
Type of cell line iPSC 
Origin Human 
Additional origin info required 
for human ESC or iPSC 
Age: 21 
Sex: Male 
Ethnicity if known: Caucasian 
Cell Source Dermal fibroblasts 
Clonality Clonal 
Associated disease Stargardt disease 
Gene/locus ABCA4/1p22.1 
Date archived/stock date 13/07/2020 
Cell line repository/bank https://hpscreg.eu/cell-line/LEIi018-A 
Ethical approval University of Western Australia Human Research 
Ethics Committee RA/4/1/7916   
1. Resource utility 
Mutations in the ATP-binding cassette transporter gene (ABCA4) 
cause Stargardt disease (STGD1) Allikmets et al. (1997), which exhibits 
a wide spectrum of retinal phenotypes. The iPSC line reported here was 
generated from a STGD1 patient carrying compound heterozygous 
mutations in the ABCA4 gene and will provide a powerful resource for 
disease modelling studies. 
2. Resource details 
The functional effects of the majority of known ABCA4 mutations are 
yet to be explored and novel mutations continue to emerge. The avail-
ability of in silico prediction algorithms, paralleled with the development 
of in vitro functional assays have contributed to our understanding of the 
consequences of certain ABCA4 variants on splicing. However, given the 
high degree of alternative splicing utilized by human retinal cells, Pan 
et al. (2008), it is essential that the effects of mutations in retinal genes 
such as ABCA4 are assessed in the affected retinal cell types. Here, we 
report the generation and characterization of an iPSC line from a STGD1 
patient carrying biallelic ABCA4 mutations, c.[5461–10T>C;5603A>T]; 
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[6077T>C]. 
The male patient presented with poor vision at age 7 years and was 
diagnosed with Stargardt disease at 9 years. Biallelic ABCA4 c. 
[5461–10T>C;5603A>T];[6077T>C] mutations were identified by 
Sanger sequencing of patient and parental DNA. At age 21, his visual 
acuity was 20/200 in both eyes and fundus imaging showed extensive 
fleck lesions throughout the retina with central atrophy. Dermal fibro-
blast cultures were previously derived from a skin biopsy from the pa-
tient Huang et al. (2020), and transfected with iPSC reprogramming 
episomes carrying OCT4, SOX2, KLF4, L-MYC, LIN28 and mp53DD. After 
4 weeks, a clonal iPSC line (LEIi018-A) was selected for expansion and 
characterization (Table 1). The LEIi018-A iPSC line displayed the typical 
morphology of pluripotent stem cell colonies (Fig. 1A). The expression 
of the pluripotency markers OCT4, NANOG, SOX2 and KLF4 was 
demonstrated by immunocytochemistry at passage 34 (Fig. 1A). Cell 
nuclei were labelled with DAPI (Fig. 1A). The ABCA4 c. 
[5461–10T>C;5603A>T];[6077T>C] mutations were confirmed in the 
LEIi018-A iPSC line by Sanger sequencing (Fig. 1B). Quantitative poly-
merase chain reaction (qPCR) analysis demonstrated similar levels of 
OCT4, NANOG, SOX2, KLF4 and MYC expression in LEIi018-A (passage 
22) and in a commercial human iPSC line (HuiPSC, Cat#A18945, 
ThermoFisher, Fig. 1C). The capacity of the LEIi018-A (passage 35) to 
differentiate into three germ layers was demonstrated by the upregu-
lation of markers of ectoderm (PAX6, OTX1), mesoderm (TBXT, NKX2.5) 
and endoderm (AFP, SOX17, FOXA2) lineages in differentiating 
embryoid body (EB) cultures (Fig. 1D). LEIi018-A was negative for both 
reprogramming episomes (Fig. 1E) and mycoplasma test at passage 16 
(Fig. 1F), whilst episome specific products (544 bp and 666 bp) were 
detected in a positive control consisting of iPSC at passage 3 and my-
coplasma specific product (504 bp) was detected in the positive control 
samples (Fig. 1E-F). The 130 bp GAPDH internal control product was 
amplified from LEIi018-A (Fig. 1E-F). Digital karyotyping of LEIi018-A 
was performed using the Infinium Human CoreExome-24 Beadchip 
SNP array (Illumina, San Diego, California, United States) with genome- 
wide copy number variation (CNV) profiling, demonstrating both lines 
were male and had a normal diploid karyotype (46, XY). Analysis of the 
B allele frequencies and LogR ratios of ≈500,000 single nucleotide 
polymorphisms located across the genome demonstrated an absence of 
reprogramming-induced chromosomal rearrangements in LEIi018-A 
(passage 16, Fig. 1G). Analysis of 16 microsatellite markers confirmed 
LEIi018-A was derived from the patient’s fibroblasts (FB) (data not 
shown). 
3. Materials and methods 
Ethics: This work was approved by the University of Western 
Australia Human Research Ethics Committee (RA/4/1/7916) with 
written consent from the patient, and performed in accordance with the 
National Health & Medical Research Council of Australia National 
Statement on Ethical Conduct in Human Research (2007, updated 2018) 
and the Declaration of Helsinki. 
Cell culture: Fibroblasts were cultured in DMEM (11995065, Gbico) 
supplemented with 10% fetal bovine serum (FBS, 26140079, Gibco) and 
Antibiotic-Antimycotic (15240062, Gibco). The Epi5™ Episomal iPSC 
Reprogramming Kit (A15960, Invitrogen) was used for reprogramming. 
Fibroblasts (1 × 105 cells) were electroporated using the NEON elec-
troporation system (Invitrogen) (three 10 ms 1650 V pulses in a 10 μl 
tip) and seeded into a geltrex (A1413302, Gibco)-coated well containing 
fibroblast culture medium. At Day 4, medium was changed to DMEM/ 
F12 (11320082, Gibco) supplemented with N2 (17502001, Gibco), B27 
(17504001, Gibco) and 100 ng/mL basic Fibroblast Growth Factor 
(bFGF, 78134, StemCell Technologies) for 2 weeks, then to TeSR-E8 
medium (05990, StemCell Technologies). IPSC colonies were picked 
for clonal expansion after 4 weeks. IPSC were passaged onto geltrex- 
coated plates using TrypLE Express Enzyme (12604021, Gibco) every 
4–5 days using a split ratio of 1:3–1:6. All cell cultures were incubated at 
37 ◦C with 5% CO2. 
Trilineage differentiation: EBs were differentiated by seeding iPSC 
clusters into suspension culture plates containing mTesR1 medium 
(85850, StemCell Technologies) and 10 µM Y27632 (ab120129, 
Abcam). Media was changed after 48 h to DMEM/F12 supplemented 
with 20% knockout serum replacement (KSR, 10828028, Gibco), MEM- 
non essential amino acids (MEM-NEAA, 11140050, Gibco) and anti-
biotic–antimycotic. Half media changes were performed daily. EBs were 
harvested at Day 14. 
RNA Analysis: RNA was isolated using MagMAX TM -96 Total RNA 
Isolation kit (AM1830, Applied Biosystems). qPCR was performed with 
RT2SYBR Green qPCR Mastermix (330503, Qiagen) on the BioRad CFX 
Connect Real-Time System (45 cycles, 95 ◦C for 30 s, 60 ◦C for 60 s). 
Gene expression was normalized to GAPDH expression. Primers used are 
listed in Table 2. 
Immunocytochemistry: iPSCs were fixed with 4% para-
formaldehyde for 15 min at 37 ◦C, washed with PBS and incubated with 
blocking buffer (5% normal goat serum in PBS containing 0.3% Triton 
X100) for 1 h at room temperature, followed by incubation with primary 
antibodies at 4 ◦C overnight. Secondary antibodies and DAPI (1 µg/mL) 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Bright field Normal Fig. 1, panels A 
Phenotype Qualitative analysis 
Immunocytochemistry 
Positive for the pluripotency markers: OCT4, NANOG, SOX2, KLF4 Fig. 1, panels A 
Quantitative analysis 
RT-qPCR 
Positive for the pluripotency markers OCT4, NANOG, SOX2, KLF4, C- 
MYC 
Fig. 1, panel C 
Genotype Karyotype (the Infinium Human CoreExome-24 
Beadchip SNP array) and resolution 
46XX, 
Resolution 500 kb 
Fig. 1, panels F 
Identity  STR analysis performed  
STR analysis Matched at 16 loci Archived with 
journal 
Mutation analysis (IF 
APPLICABLE) 
Sequencing ABCA4 c.[5461–10T>C;5603A>T];[6077T>C] Fig. 1, panels B 
Southern Blot OR WGS N/A N/A 
Microbiology and virology Mycoplasma Mycoplasma testing by PCR: Negative Fig. 1, panel E 
Differentiation potential Embryoid body formation Upregulation of ectoderm (PAX6, OTX1), mesoderm (TBXT, NKX2.5) 
and endoderm (AFP, SOX17, FOXA2) markers 
Fig. 1, panel D 
Donor screening 
(OPTIONAL) 
HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A 
Genotype additional info 
(OPTIONAL) 
Blood group genotyping N/A N/A 
HLA tissue typing N/A N/A  
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Fig. 1. STR analysis.  
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diluted in blocking buffer were applied for 1 h at room temperature. 
Antibodies are listed in Table 2. 
DNA Analyses: DNA was extracted using the FlexiGene DNA kit 
(51206, Qiagen). Karyotyping was performed by the Australian Genome 
Research Facility (AGRF), using the Infinium HumanCoreExome-24 
Beadchip SNP array (Illumina, San Diego, California, United States), 
followed by CNV analysis using GenomeStudio 2.0 software with the 
CNVpartition 2.0 plugin (Illumina). Microsatellite analysis was per-
formed by AGRF using the Promega Powerplex 16H system (Promega, 
Madison, Wisconsin, United States). PCR for Sanger sequencing was 
performed on a GeneTouch Thermal Cycler (35 cycles, 94 ◦C for 30 s, 
60 ◦C for 60 s, 72 ◦C for 120 s). Mycoplasma testing was performed using 
the Mycoplasma Testing Kit (#091, Media and Monoclonal Labora-
tories, Harry Perkins Institute of Medical Research, Fig. 1G). Primers 
used are listed in Table 2. 
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Table 2 
Reagents details.   
Antibodies used for immunocytochemistry/flow-cytometry  
Antibody Dilution Company Cat # RRID 
Pluripotency Markers Rabbit anti-OCT4 1:1000 Sino biological 
101282-T02 
AB_2810309  
Rabbit anti-NANOG 1:1000 Sino biological 101286-T34 AB_2810308  
Rabbit anti-SOX2 1:1000 Sino Biological 101284-T42 AB_2810307  
Rabbit anti-KLF4 1:100 Invitrogen 710,659 AB_2532749 
Secondary antibodies Goat anti-Rabbit AlexaFluor 546 1:250 Invitrogen A11035 AB_2534093   
Primers  
Target Size of amplicon Forward/Reverse primer (5′-3′) 
Episomal Plasmids (PCR) Episomal vectors (OriP) 544 bp TTCCACGAGGGTAGTGAACC/TCGGGGGTGTTAGAGACAAC  
Episomal vectors (EBNA1) 666 bp ATCGTCAAAGCTGCACACAG/CCCAGGAGTCCCAGTAGTCA 
Mycoplasma Primers (PCR) Mycoplasma DNA 504 bp YGCCTGVGTAGTAYRYWCGC/GCGGTGTGTACAARMCCCGA 
Pluripotency Markers (qPCR) OCT4 105 bp CCTGAAGCAGAAGAGGATCACC/AAAGCGGCAGATGGTCGTTTGG  
NANOG 114 bp CTCCAACATCCTGAACCTCAGC/CGTCACACCATTGCTATTCTTCG  
SOX2 134 bp GCTACAGCATGATGCAGGACCA/TCTGCGAGCTGGTCATGGAGTT  
KLF4 110 bp CATCTCAAGGCACACCTGCGAA/TCGGTCGCATTTTTGGCACTGG  
C-MYC 128 bp CCTGGTGCTCCATGAGGAGAC/CAGACTCTGACCTTTTGCCAGG 
Trilineage Markers (qPCR) PAX6 130 bp CTGAGGAATCAGAGAAGACAGGC/ATGGAGCCAGATGTGAAGGAGG  
OTX1 159 bp CTACCCTGACATCTTCATGCGG/GGAGAGGACTTCTTCTTGGCTG  
TBXT 152 bp CCTTCAGCAAAGTCAAGCTCACC/TGAACTGGGTCTCAGGGAAGCA  
NKX2.5 146 bp AAGTGTGCGTCTGCCTTTCCCG/TTGTCCGCCTCTGTCTTCTCCA  
AFP 96 bp TGAGCACTGTTGCAGAGGAG/TTGTTTGACAGAGTGTCTTGTTGA  
SOX17 111 bp ACGCTTTCATGGTGTGGGCTAAG/GTCAGCGCCTTCCACGACTTG  
FOXA2 133 bp GGAACACCACTACGCCTTCAAC/AGTGCATCACCTGTTCGTAGGC 
House-Keeping Genes (qPCR) GAPDH 130 bp GTCTCCTCTGACTTCAACAGCG/ACCACCCTGTTGCTGTAGCCAA 
Targeted mutation sequencing ABCA4 765 bp CCTTGAGGCACTGCTTGTAAG/GGTCAGGAGGAAGTACACCAC  
ABCA4 490 bp CAGGATTCAGTTTCTAACCG/CTAGAACAGTACTTGGCACA  
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